Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Three projects from MSD were amongst 10 from across the University to receive funding from the second-round of the Public Engagement with Research Seed Fund [http://www.ox.ac.uk/research/public-engagement/support-researchers].

Dr Marta Valente Pinto, is based in the Oxford Vaccine Group, part of the Department of Paediatrics, where she studies Whooping cough, a highly contagious respiratory disease that, although to some extent preventable by vaccines, continues to cause a significant number of infections in developed countries. Her project will involve the creation and delivery of workshops in Thames Valley Primary and Secondary Schools to help children and parents understand more about the disease, and to make more informed decisions about vaccinations.

Dr Marco J. Haenssgen, based in the Centre for Tropical Medicine & Global Health, part of the Nuffield Department of Medicine, received funding  to evaluate the process and impact of health-themed science theatre as part of ongoing public engagement activities at the Mahidol Oxford Tropical Medicine Research Unit. In order to engage the public with its research, MORU is collaborating with B-floor Theatre to produce a performance entitled Fishy Clouds, which explores antimicrobial resistance through puppet plays for both children and adults in Thailand. The social outcomes of drama performances are difficult to evaluate and little guidance exists in the evaluation research literature. This project will test out methods for evaluation, and in doing so inform the theory and practice of evaluating such engagement activities for others. 

Simon Knight, based at the Oxford Transplant Centre, part of the Nuffield Department of Surgical Sciences, was awarded funding to develop an online patient advisory panel for renal and transplant research in Oxford, which will provide a patient perspective on upcoming research projects and patient materials.

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.